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ABSTRACT

COPY NUMBER VARIANT ANALYSIS OF PATIENTS WITH MALFORMATIONS
OF CORTICAL DEVELOPMENT.
Luis Kolb, Kaya Bilguvar, Michael Di Luna, Chris Mason, Yasar Bayri, Ali Ozturk,
Zulfikar Ayer, Nikhil Nayak, and Murat Gunel. Department of Neurosurgery, Yale
University School of Medicine, New Haven, CT.

Copy Number Variants (CNVs) are DNA fragment that are approximately 1 kilobase (kb)
to several megabases for which copy-number differences have been revealed by
comparison of two or more genomes. The Human Genome project has led to the
identification of close to 1500 of these variable regions covering 12% of the human
genome. Even though many of these variants are considered to be benign, some of these
genomic rearrangement have been found to be disease causing, including several nervous
system disorders such as Charcot-Marie-Tooth, Williams-Beuren Syndrome, and PraderWilli syndrome.

In this study we have performed copy number variant analysis on 252 patients with
cortical malformations. Cortical malformations represented in our cohort included
patients with cortical dysplasia (95), lissencephaly (33), heterotopia (10), pachygyria (8),
and polymicrogyria (20), among other diseases.

Two disease-causing copy number variants were identified, and those two diseases are
the focus of this manuscript: a diffuse villous hyperplasia of the choroid plexus, and
cerebellar atrophy with pachygyria.

Diffuse villous hyperplasia of the choroid plexus is a rare cause of hydrocephalus not
amenable to shunting alone. Tetrasomy of the short arm of Chromosome 9 was identified
using high-resolution genomic array mapping, broadening the phenotype of this
described entity to include diffuse villous hyperplasia of the choroid plexus.

Congenital ataxia with cerebellar hypoplasia is a heterogeneous group of disorders that
presents with motor disability, hypotonia, incoordination, and impaired motor
development. A homozygous deletion in the VLDLR gene was identified using high
density single nucleotide polymorphism (SNP) micro arrays in a Turkish family with two
siblings affected with cerebellar atrophy and pachygyria. Previous identification of
VLDLR mutations in a Turkish family with quadrupedal gait led to various speculations
ranging from “reverse evolution” to cultural influences. Discovery of disease causing
homozygous deletions in a new Turkish family, which maintained bipedal movement,
constitutes significant evidence against these speculations.
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INTRODUCTION

Malformations of cortical development (MCD) are an important cause of epilepsy and
developmental delay.1 It is estimated that up to 40% of children with refractory epilepsy
have a cortical malformation.2 This group of disorders is composed of a large spectrum of
abnormalities related to cortical development with varied genetic etiologies, anatomic
abnormalities, and clinical manifestations. While prior to 1980 many of these disorders
were solely diagnosed at autopsy, the use of magnetic resonance imaging (MRI) has
dramatically improved our ability to recognize these diseases.

Cerebral cortical development involves a series of highly organized and complex events,
broadly including neural stem cell proliferation, migration, and neuronal differentiation.
Disruptions of any of these various stages may result in malformations of cortical
development. Disorders due to abnormalities of cell proliferation may cause
microcephaly (small brain), megalencephaly (large brain), or cortical dysplasia (focal
areas of abnormal neuronal architecture). Disorders of initiation of neuronal migration
may result in periventricular heterotopia (PH) (abnormal nodules of neurons located
along the ventricular wall). Disorders of later migration and motility cause disruption of
the normal 6-layered cortex, such as classic lissencephaly (smooth brain) and subcortical
band heterotopia (heterotopic neurons located midway between the surface of the brain
and lateral ventricles). Finally, disorders of neuronal arrest can result in neurons that fail
to stop upon reaching their intended destination in the cerebral cortex and over migrate
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onto the cortical surface as is the case in cobblestone lissencephaly. Although cortical
development has been separated into these stages, there is a significant overlap with no
clear juncture, and many abnormalities may cause dysfunction at more than one level.
Thus, malformation syndromes are typically classified based on the earliest assumed
disruption of development. These concepts serve as the basis for the latest classification
scheme for these disorders.3 (Table 1)

The pathogenesis of these malformations is thought to be multifactorial. Genetic
mutations or environmental insults, acquired either in utero at different stages of brain
development or during the perinatal or postnatal period after corticogenesis, may all
contribute to the development of these diseases. 4, 5 The extent of the malformation
syndrome will be determined by the timing, severity, type of environmental influences,
and genetic factors.
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Table 1: Classification of diseases of cortical development.
I.

II.

III.

IV.

Malformations due to abnormal neuronal and glial proliferation or
apoptosis
a. Decreased proliferation / increased apoptosis or increased proliferation /
decreased apoptosis – abnormalities of brain size
i. Microcephaly with normal to thin cortex
ii. Microlissencephaly (extreme microcephaly with thick cortex)
iii. Microcephaly with extensive polymicrogyria
iv. Macrocephalies
b. Abnormal proliferation (abnormal cell types)
i. Nonneoplastic
1. Cortical hamartomas of tuberous sclerosis
2. Cortical dysplasia with balloon cells
3. Hemimegalencephaly
ii. Neoplastic (associated with disordered cortex)
1. Dysembryoplastic neuroepithelial tumor
2. Ganglioglioma
3. Gangliocytoma
Malformations due to abnormal neuronal migration
a. Lissencephaly / subcortical band heterotopia spectrum
b. Cobblestone complex / congenital muscular dystrophy syndromes
c. Heterotopia
i. Subependymal (periventricular)
ii. Subcortical (other than band heterotopia)
iii. Marginal glioneuronal
Malformations due to abnormal cortical organization (including late
neuronal migration)
a. Polymicrogyria and schizencephaly
i. Bilateral polymicrogyria syndromes
ii. Schizencephaly (polymicrogyria with clefts)
iii. Polymicrogyria or schizencephaly as part of multiple congenital
anomaly / mental retardation syndromes
b. Cortical dysplasia without balloon cells
c. Microdysgenesis
Malformations of cortical development, not otherwise classified
a. Malformations secondary to inborn errors of metabolism
i. Mictochondrial and pyruvate metabolic disorders
ii. Peroxisomal disorders
b. Other unclassified malformations
i. Sublobar dysplasia
ii. Others

Adapted from Barkovich et al. 3.
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Work in determining the genetic basis of various MCD has given us greater insight and
understanding into the underlying pathophysiology of these disorders. Different
mutations of the same gene can cause different phenotypes, likely based on the degree of
protein dysfunction (so termed genotype-phenotype correlation). Loss or disruption of the
functional domains within a gene in some cases is enough to determine the phenotype of
the disorder. Alternatively, specific mutations in a given gene can also lead to a gain of
function for the aberrant protein. Mosaicism can occur when the mutation is present in a
subpopulation of cells, whereas germ line mutations typically lead to expression of the
mutant gene in all cells. Functional mosaicism occurs due to X-inactivation in which the
mutation is present on 1 X chromosome but not the other. The mutant gene is then
expressed only in cells in which the mutant gene is found on the active X chromosome,
explaining why affected females often are less severely affected than males. An
understanding of some of the underlying genetic basis for these disorders will play an
important role in genetic counseling of affected individuals and their families.1

Traditionally, genetic diseases are classified as chromosomal (numerical or structural);
Mendelian (or single gene disorders); multifactorial/polygenic complex diseases;
congenital anomalies; and diseases associated with specific mitochondrial gene
mutations. Apart from chromosomal disorders, essentially all genetic disorders result
from either some sort of alteration or mutation occurring in a specific gene (single gene
diseases) or from the involvement of multiple loci spread across the human genome
(polygenic disorders). Each of these disorders has major impact on patients. The majority
of chromosomal disorders affect patients before birth and carry serious health burden
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throughout childhood and during the early years of life. Single gene diseases peak around
mid-childhood and pose a real medical and health burden from the perinatal period to
adult age. In contrast polygenic/multifactorial disorders present late, with the exception
of developmental anomalies requiring active multi-disciplinary care during the early life.6

Genetic studies on human disease have been for long time limited to the investigation of
single gene diseases. These monogenic disorders tend to be rare, severe and follow clear
patterns of inheritance that can be accurately traced through generations. Once these
diseases were adequately phenotyped, specific candidate genes within linkage intervals
were searched for mutations in the patients and family members. More than 2000
diseases have been identified in this manner, with most of these diseases caused by single
base mutations that lead to missense or nonsense mutations according to the Database of
Genomic Variants (http://projects.tcag.ca/variation/). For example, four autosomal
recessive genes are associated with microcephaly: Microcephalin7, ASPM (abnormal
spindle-like, microcephaly-associated)8 9, CDK5RAP2 (CDK5 regulatory subunitassociated protein 2) 10, and CENPJ (centromere protein J) 10. These genes seem to play a
role in cell division during neurogenesis at the ventricular neuroepithelium by playing an
important role in the regulation of microtubules and cell cycle progression during cell
division.10 11-13 X-Linked mutations in FLNA 14-16and autosomal recessive mutations in
ARFGEF2 (ADP-ribosylation factor guanine exchange factor 2) 17 are associated with
Periventricular Heterotopia; and Subcortical band heterotopia is caused by mutations in
the microtubule-associated DCX gene18. Several genes have been identified giving rise to
classic lissencephaly: LIS1 (Lissencephaly1, autosomal dominant),19 DCX (Doublecortin,
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X-linked dominant),20 TUBA1A (Tubulin alpha 1A, autosomal dominant),21, 22 ARX
(Aristaless, X-linked dominant),23 and RELN (Reelin, autosomal recessive) 23, with
causative genes having characteristic differences in the clinical and radiographic
presentation. Cobblestone lissencephaly follows an autosomal recesive intheritance
pattern and has been associated with POMT124, POMT225 , POMGnT126, and Fukutin27;
genes involved in the glycosylation of α dystroglycan, a receptor for multiple
extracellular molecules that maintains the stability of the cell surface. Bilateral frontal
and parietal polymicrogyria seem to be associated with mutations in the G-proteincoupled receptor gene (GPR56)28, 29, assumed to play a role in the regional organization
of the brain (Table 2).
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Table 2: Genetic basis of malformations of cortical development
Syndrome

Locus

Gene

Protein

Autosomal recessive periventricular
heterotopia / micrcocephaly

8p23

MCPH1

Microcephalin

Autosomal recessive periventricular
heterotopia / micrcocephaly

1q31

ASPM

Abnormal spindle-like
microcephaly

Autosomal recessive microcephaly

9q34

CDK5RAP2

CDK-5 regulatoryassociated protein 2

Autosomal recessive microcephaly

13q12.2

CENPJ

Centromere-associated
protein J

Autosomal recessive periventricular
heterotopia / micrcocephaly

20q13.13

ARFGEF2

ARFGEF2

Amish lethal microcephaly

17q25.3

SLC25A19

Seckel syndrome 1

3q22-q24

ATR

Isolated lissencephaly sequence

Xq22.3-q23

DCX-XLIS

DCX

Subcortical band heterotopia

Xq22.3-q23

DCX-XLIS

DCX

Miller-Dieker syndrome

17p13.3

Several
contiguous

PAFAH1B1, 14-3-3 and
others

Isolated lissencephaly sequence

17p13.3

LIS1

PAFAH1B1

Subcortical band heterotopia

17p13.3

LIS1

PAFAH1B1

Lissencephaly with cerebellar hypoplasia

7q22

RELN

Reelin

X-linked lissencephaly with abnormal
genitalia

Xp22.13

ARX

Aristaless-related
homeobox protein

Fukuyama congenital muscular
dystrophy

9q31

FCMD

FCMD or Fukutin

Nuclear mitochondrial
deoxynucleotide carrier
Ataxia telangiectasia
and Rad3 related protein
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Table 2: Genetic basis of malformations of cortical development (Cont.)
Syndrome

Locus

Gene

Protein

1p33-p34

POMGnT1

Unknown

19q13.3

FKRP

Fukutin-related protein

19q13.3

FKRP

Fukutin-related protein

22q12.3-q13.1

LARGE

9q34.1

POMT1

O-Mannosyl-transferase
1

19q13.3

FKRP

Fukutin-related protein

9q31

FCMD

FCMD

Xq28

FLNA

Filamin-A

20q13.3

ARFGEF2

BIG2

5p15

Unknown

Unknown

9q32

TSC1

Hamartin

16p13.3

TSC2

Tuberin

16q13

GPR56

Unknown

2q21.3

RAB3GAP

Xq28

Unknown

Muscle-eye-brain disease
Muscle-eye-brain disease
Congenital muscular dystrophy
Congenital muscular dystrophy
Walker-Warburg syndrome

Walker-Warburg syndrome
Walker-Warburg syndrome
Bilateral periventricular nodular
heterotopia
Bilateral periventricular nodular
heterotopia + microcephaly
Bilateral periventricular nodular
heterotopia
Tuberous sclerosis chromosome 1
Tuberous sclerosis chromosome 2
Bilateral frontoparietal polymicrogyria
Warburg microsyndrome 1
Bilateral perisylvian polymicrogyria

Adapted from Barkovich et al. 3.

Unknown
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Recent advances in molecular genetics have enabled us to identify specific groups of
disorders that result from previously uncharacterized mechanisms. Often these disorders
do not conform to the standard basic principles of genetics, and involve specific areas of
the human genome. A broad term ‘genomic disorders’ has been coined to describe these
conditions6. Broadly, this group of disorders can be subdivided into disorders in the
genome architecture, trinucleotide repeat disorders, chromosome breakage disorders,
non-disjunction disorders, and complex genomic diseases. 6

These disorders follow unusual non-traditional inheritance mechanisms that involve
genomic regions that directly or indirectly influence the regulation and expression of one
or more genes manifesting in complex phenotypes. The evolution of the mammalian
genome has resulted in the duplication of genes, gene segments and repeats of gene
clusters.30 This aspect of genome architecture provides recombination hot spots between
non-homologous regions of chromosomes that are distributed across the whole genome.
These genomic regions become susceptible to further DNA rearrangements that may be
associated with abnormal phenotypes. 31-34

These ‘hotspot’ regions usually lie within genomic regions referred to as Low Copy
Number Repeats (LCR). LCR are region specific DNA blocks usually 10 to 300
kilobases (kb) in size and of > 95% to 97% similarity to each other that usually map to
two or three locations in the genome.35-37 It is estimated this regions account for ~5% of
the human genome. They can contain any standard constituent of genomic DNA,
including gene families, gene containing structural motifs, or sequences of unknown
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function present in clusters or dispersed through the genome. Examples include the HLA
and related genes, actins, zinc-finger genes, and the CRI-S232 sequence family. LCRs are
distinguished from highly repetitive sequences in the human genome by their high degree
of sequence similarity and large numbers, and often appear to locate preferentially near
centromeres and telomeres in human chromosomes.38, 39

The term ‘genome architecture disorder’ refers to a disease that is a result of an alteration
of the genome that results in complete loss, gain or disruption of the structural integrity of
dosage sensitive genes.40, 41 Disruption in the function of dosage sensitive gene may
result from number of mechanisms including gene interruption, gene fusion, position
effect, unmasking of a recessive allele, presence of a functional polymorphism, and gene
transvection effect.6 Notable examples include a number of microdeletion /
microduplication syndromes such as Williams- Beuren syndrome 42, Prader-Willi
syndrome43, Angelman syndrome44, Smith Magenis syndrome45, Potoki Lupski
syndrome45, DiGeorge syndrome46, and Neurofibromatosis type 147. (Table 3) In these
conditions there is a critical rearranged genomic segment flanked by large (usually > 10
kb), highly homologous low copy repeat structures that can act as recombination
substrates.48 Meiotic recombination between non-allelic LCR copies, also known as nonallelic homologous recombination, can result in deletion or duplication of the intervening
segment6. The phenotype of these disorders is distinctly recognizable with particular
clinical and facial dimorphic features.
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An increasing number of Mendelian diseases are being recognized to result from
recurrent inter and intra chromosomal rearrangements involving unstable genomic
regions.6 These genomic regions have been shown to be predisposed to non-allelic
homologous recombination by proximity to ‘hot spot’ genomic segments.49 Large
genomic deletions and duplications have been reported as being pathogenic in cases of
various diseases, such as Duchenne and Becker muscular dystrophies, familial breast
cancer, hereditary nonpolyposis colorectal cancer, and Williams-Beuren syndrome.
(Table 4) Previously, our lab reported a homozygous microdeletion in the parkin gene
(PARK 2) in a Turkish family in which six members were afflicted with autosomal
recessive Parkinsonism. 50 Mutations in the PARK2 gene had been previously shown to
be associated with early-onset Parkinson’s disease51.

Even though traditionally when one considers what constitute ‘genetic diseases’ one
usually refers to traits inherited in a Mendelian fashion and resulting from base pair
changes that alter an encoded protein’s structure, function and regulation, clinical
conditions observed in genetics are sporadic in >97% of the cases. Often these cases are
not due to mutant genes, but instead result from genomic copy number variations.52 2-3%
of children are born with a major birth defect and often these are sporadic in nature.53, 54
Chromosomal anomalies, such as trisomy 21, have been shown to be responsible for birth
defects in ~0.2% of live births.55 Recessive traits are thought to compose a similar
proportion .55 De novo point mutations are also known to cause sporadic disease as is in
common cases of achondroplasia, neurofibromatosis type 1, and tuberous sclerosis, as
well as multiple other diseases.52
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Direct estimates of human per-nucleotide rates for spontaneous mutations have been
estimated to between 0.5 x 10-8 to 3 x 10-8 from the per-locus mutation rates and
sequences of de novo nonsense nucleotide substitutions, deletions, insertions, and
complex events causing autosomal dominant and X-Linked diseases56. In the context of
the 3 x109 bp haploid human genome, this rate corresponds to ~60 new mutations per
germ cell, with male germ cells having more than female germ cells as most point
mutations presumably represent DNA replication or repair errors. Approximately 2%
(2.4) of them will affect exonic sequences, thus about two exons (and thus genes) have a
de novo base-pair change. Of these, at least one third are likely to have little effect as
they would lie in the third position of a codon.52 Thus, it seems paternal age affect is the
most likely cause of ‘sporadic cases’ often being found among the last-born children of a
sibship.57, 58

In contrast, the de novo locus-specific mutation rates for genomic rearrangements has
been calculated to be between 10-6 and 10-4 from sporadic microdeletion syndromes,
common autosomal dominant or X-Linked disease prevalence rates, by direct
measurement by either sperm PCR at the alpha globin or t(11;22) recombination
breakpoint sites, and by genomic assays comparing child to parents in trios.52 This rate is
at between 2 and 4 orders of magnitude (100 to 100,000 fold) greater than observed rates
of de novo locus-specific mutation point mutations. It appears that genomic
rearrangements are more common than point mutations, and that the mechanisms causing
them are more prevalent as well.
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There appears to be three primary recombination mechanisms responsible for generating
deletions and duplications that cause genomic rearrangements that can be associated with
genomic disorders.49 Nonallelic homologous recombination (NAHR), described above,
appears to be the more frequent mechanism for specific regions of the genome that have
architecture that favors genomic instability, and has been proposed as the main
mechanism for genomic rearrangements due to the proximity of most genomic
rearrangements to low copy repeats40, 59. This seems to be especially true for most of the
recurrent rearrangements that share a common size, show clustering of breakpoints, and
recur in multiple individuals. In this process, non-allelic copies of LCRs, instead of the
copies at the usual allelic positions, are aligned in meiosis or mitosis. This
‘misalignment’ results in genomic rearrangements in the progeny cells. When the two
LCRs are located on the same chromosome and in direct orientation, the resulting
rearrangement is either a deletion or duplication. When the LCRs are in the same
chromosome but in opposite orientation, the process results in inversion of the fragment
flanked by them. Non-allelic homologous recombination on different chromosome results
in chromosomal translocation.41

Nonhomologous end joining (NHEJ) and the Fork Stalling and Template Switching
(FoSTeS) have been proposed as the other two mechanisms responsible for genomic
rearrangements, especially for the non-recurrent cases. Non-recurrent rearrangements are
of different sizes in each patient, but may share a small region of overlap whose change
in copy number may result in shared clinical features among different patients.59 These
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non- recurrent rearrangements might be stimulated by low copy repeat regions, as well as
might be mediated by highly homologous repetitive sequences such as the Alu, and LINE
sequences.

Nonhomologous end joining (NHEJ), which plays a critical role in V D J recombination the process by which B-cell and T-cell diversity is generated, is one of the two major
mechanisms used by eukaryotic cells to repair both physiological and pathological double
stranded breaks (DSB).60, 61 NHEJ is considered to be the major mechanism responsible
for joining translocated chromosomes in cancer.61 The process proceeds in four steps:
detection of DSB; molecular bridging of both broken DNA ends; modification of the
ends; and ligation of the ends. Sequence studies on non-recurrent deletions in the DMD
gene and the PLP1 gene, as well as duplications on the PLP1 have found evidence these
genomic rearrangements are caused by the NHEJ mechanism.62, 63 It has been proposed
that the first step of the rearrangement is when a single DSB occurs in one strand;
followed by the broken ends being invaded and copied from the sister chromatid; and
finally the ends being rejoined via NEHJ.

Some rearrangements are far more complex than those able to be explained by NAHR
and NEHJ mechanisms. To explain these more complex events, the Fork Stalling and
Template (FoSTees) model has been proposed.64 In this model, during DNA replication
the DNA replication fork stalls at one position causing the lagging strand to disengage
from the original template, and transfer and anneal to another replication fork in physical
proximity. The DNA replication process then ‘primes’ again, and continues DNA
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synthesis65. Switching to another folk located downstream would result in a deletion,
while switching to a fork upstream would result in duplication. The process of
disengaging, invading/annealing, synthesis/extension could occur multiple times resulting
the observed complex rearrangements.49 Although still very limited, preliminary data
implies that FoSTeS might be a major mechanism of duplication, and might have also
been the driving force in the origin of Low Copy Repeats.

Eighteen years ago it became evident that genomic rearrangements and gene dosage
effects, rather than the classical model of coding region DNA sequence mutations, could
be responsible for nervous system diseases when a duplication in CMT1A was
discovered to be responsible for Charcot-Marie Tooth neuropathy type 1a, a common,
autosomal dominant adult-onset neurodegerative disease.66, 67 Now, several
neurodegenerative and neurodevelopmental disorders are known to be caused by
disparate recurrent and non-recurrent genomic rearrangements.68 These genomic
disorders include peripheral and central nervous system neuropathies, well-recognized
syndromes with characteristic phenotypes, and also a growing group of psychiatric
illnesses. Some of these disorders include the deletion in PMP22 causing hereditary
neuropathy with liability to pressure palsies (HNPP), and some of the recurrent
microdeletion disorders previous mentioned like Williams-Beuren Syndrome42,
Angelman syndrome44, and Prader Willi syndrome43.
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Several new genomic disorders caused by genomic rearrangements leading to nervous
system diseases have been recently recognized. Duplications of the genomic region
deleted in Williams-Beuren syndrome have been described, with patients characterized
by prominent speech delay.42, 69, 70 Tandem duplications of LMNB1 have been reported to
cause adult-onset autosomal dominant leukodystrophy71, and duplications in
PAFAH1B1/LIS1 and YWHAE –genes deleted in lissencephaly (PAFAH1B1/LIS1 alone)
and Miller-Dieker syndrome (both) were found in patients with developmental delay72, 73.
Finally, two new microdeletion syndromes have been described in 17q21.3174, 75 and
15q13.376, and the reciprocal duplications, have been recognized.

With the advent of the completion of the Human Genome, thousands of single nucleotide
polymoprhisms have been discovered and their use as common polymorphic markers has
revolutionized genome-wide studies. A SNP is a variation of a single nucleotide in the
DNA sequence that occurs between members of the same species. SNPs may fall within
the coding sequence of genes, intronic sequence of genes, or in intergenic regions. Some
SNPs may contribute directly to disease phenotype by altering the gene function,
especially those lying within the coding sequences. The majority, though, are located
outside protein coding regions.77

There are approximately 10 million SNPs with a minimum allele frequency of 1% that
have been discovered spread throughout the genome.78 A minimum allele frequency of
1%, which means the rarer allele occurs with a frequency of at least 1% of the population,
is commonly used as a cutoff when considering a single base change as a rare variant or
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polymorphisms. Assays have been developed using SNPs as markers that are cheap and
easy to perform and take advantage of SNPs being numerous, frequent and stable. These
assays are increasingly being used in genome wide studies of individuals, families and
populations.

A large, well-characterized collection of SNPs has become increasingly important in the
discovery of DNA sequence variations that affect biological function. A block of
associated SNPs in a region of the genome is called a haplotype. Many parts of the
genome exist with distinctive areas of common haplotypes, which account for most of the
individual variation within a population. The International HapMap Project is an
international collaboration with the goal of developing a haplotype map of the human
genome, which will describe the common patterns of human genetic variation.79 In many
ways this is information is thought to simplify the human genome so that instead of
having to scan through 10 million SNPs to explain human variation, it may be possible to
breakdown the genome into specific areas of increase variation that can be specifically
tagged with SNPs, thereby reducing the amount of genotyping required. The current
phase II HapMap characterizes over 3.1 million human SNPs from four geographically
diverse populations80.

In addition to the identification of thousands of SNPs, the Human Genome project has led
to the identification of a range of other DNA sequence variations such as insertions,
deletions, and translocations of various segments of chromosomes.81 The term Copy
Number Variant (CNV) was coined to describe a copy number change involving a DNA
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fragment that is approximately 1 kilobase (kb) to several megabases for which copynumber differences have been revealed by comparison of two or more genomes. These
changes can be copy-number gains (duplications or insertional transpositions, losses
(deletions), gains or losses of the same locus, or multiallelic or complex rearrangements.
This excludes insertions or deletions involving transposable elements. Even though it
was well known previous to the Human Genome Project that large duplications and
deletions have a mechanistic role in the development of a range of human genetic
diseases, it was during the Human Genome Project and subsequent studies that it was
appreciated that humans carry a far higher than expected number of CNVs.82-84 It has
been speculated there are close to 1500 variable regions covering 12% of the human
genome that equal or even surpass the number of nucleotides affected by SNPs. 85

CNV discovery will continue. Many of these CNVs are likely to represent benign
variants, but proving they do not have phenotypic consequences or that they do not
account for normal physical or behavioral traits will be a challenge. It is also a challenge
to establish a cause-and-effect relationship for a specific genomic rearrangement and a
given phenotype; and even more of a challenge to determine the dosage-sensitive gene or
genes within the genomic rearrangement. Regardless, when analyzing genetic disorders,
one should consider new mutation. Given that the frequency of de novo structural
changes can be four orders of magnitude greater than that of base pair changes, CNV
should be considered a potential significant cause of sporadic disease and Mendelian
disorders. These diseases include the malformations of cortical development detailed
above.
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STATEMENT OF PURPOSE & SPECIFIC AIMS

The purpose of this study is to utilize molecular genetics techniques, specifically SNP
genotyping, CNV analysis and homozygosity mapping, in order to find genetic mutations
that cause diseases of neural development. This manuscript details our studies on our
neurogenetics cohort and on two diseases in particular: Cerebellar Atrophy, and Choroid
Hyperplasia. Our aim is to uncover the gene mutations that cause these disorders so that
we may develop a better understanding of the pathophysiology of these diseases
specifically and malformations of neural development generally.
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METHODS

Patient Identification and Collection of Blood Samples

Approval for this study was obtained from the Yale Human Investigations Committee
(Protocol 7680). The patients afflicted with malformations of cortical development were
identified by physicians at Yale New Haven Hospital as well as collaborators at other
institutions in the United States and Europe. Diagnosis for each patient was established
by the identifying physician based on physical findings, computerized tomography (CT)
findings, and/ or magnet resonance imaging (MRI) findings. For patients identified at
Yale New Haven Hospital, the author attained consent and collected their blood samples.
For patient identified elsewhere, consent was attained and blood samples were collected
by the collaborating physicians, and Ethical Committee approval was obtained from each
institution.

Isolation of Genomic DNA

Total genomic DNA was isolated from lymphocyte nuclei using a procedure described by
Bell et al. 86. Ten milliliters of blood collected in a heparinized tube and then kept at 4°C
was mixed with 90 ml of 0.32 M sucrose / 10 mM TrisHCl (pH 7.5) / 5 mM MgCl2 / 1%
Triton X-100 at 4°C to lyse all cells. The nuclei were collected by centrifugation at 1000
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X g for 10 min. The nuclear pellet was suspended in 4.5 ml of 0.075 M NaCl / 0.024 M
EDTA (pH 8.0) with a Pasteur pipette. Then 0.5 ml of 5% sodium dodecyl sulfate and
proteinase K at 2 mg/ml were added and the mixture was incubated for approximately 12
hr at 37°C.

The digest was gently mixed with 5 ml of phenol saturated with 20 mM Tris HCl (pH
8.0). Five milliliters of chloroform / isoamyl alcohol (24:1, vol/vol) was added and
gentle mixing was continued. The phases were separated by centrifugation for 15 min at
1000 X g. The upper, aqueous, phase was removed and gently extracted with the
chloroform / isoamyl alcohol mixture. After centrifugation, the aqueous phase was
removed; 0.5 ml of 3 M sodium acetate and 11 ml of 100% ethanol (at room temperature)
were added. The DNA was precipitated by inverting the tube several times and then
removed with a Pasteur pipette and placed in 1 ml of 10 mM Tris HCl (pH 7.5) / 1 mM
EDTA. The DNA was allowed to dissolve at 4°C. From 10 ml of blood, 20-50 µg of
DNA was obtained. In cases where the yield is low, we incubate the DNA at -20°C in
the presence of ammonium acetate. Genomic DNA was isolated by the author and
laboratory technicians.

Single Nucleotide Polymorphism Genotyping and Quality Control

Single Nucleotide polymorphism genome-wide genotyping was performed on the
Illumina plataform 370 Human CNV and the Human610-Quad Beadchip (containing
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379.473 and 620,089 SNPs respectively; Illumina, San Diego, CA, USA). All procedures
were done according to manufacturer’s protocol. Briefly, 200 ng of genomic DNA was
amplified, fragmented, and hybridized to the array, and products were fluorescently
labeled and scanned with Illumina Beadstation scanner. Raw data was then uploaded in
Beadstudio v3.3 genotyping software (Illumina, San Diego, CA, USA) for further
analysis. Samples of subjects that had genotype call rates < 97% (n=6),
heterozygosity > 37% (n=3) or samples with incorrectly imputed gender (n=0)
were excluded. SNP genotyping was performed by laboratory technicians.

CNV Detection

Data was analyzed using BeadStudio v3.3 (Illumina Inc., San Diego, CA). Two metrics
were visualized using this tool: B allele frequency and log R ratio. The B allele frequency
is the theta value for an individual SNP corrected for cluster position. This parameter
provides an estimate of the proportion of times an individual allele at each polymorphism
was called A or B. In this setting, an individual who is homozygous for the B allele (BB
genotype) would have a score close to 1, an individual homozygous for the A allele (AA)
would have a score close to 0, and an individual who is heterozygous (AB) would have a
score of approximately 0.5. Significant deviations from these figures in contiguous SNPs
are indicative of a CNV. The log R ratio is defined as the log (base 2) ratio of the
observed normalized R value for the SNP divided by the expected normalized R value for
the SNPs theta value. The expected R value is calculated from the values theta and R,

23
where R is the intensity of dye labeled molecules that have hybridized to the beads on the
array and theta is the ratio of signal at each polymorphism for beads recognizing an A
allele to beads recognizing a B allele. The expected R value for any individual at any
typed SNP is calculated using a large population of typed individuals. Therefore, the ratio
of observed R to expected R in any individual at any SNP gives an indirect measure of
genomic copy number. An R value above 1 is indicative of an increase in copy number,
and an R value below 1 suggests a decrease (deletion) in copy number. While this metric
exhibits a high level of variance for individual SNPs, it does provide a measure of copy
number when log R ratio values for numerous contiguous SNPs are visualized. We
evaluated both the log R ratio and the B allele frequency plots across the genome in all
samples. (Figure 1, Figure 2)
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Figure 1: Homozygous Deletion example. Log R ratio plot. Scatter points represent
normalized log2 ratios (y) for probes along the chromosome. A segment was considered
to be significant if y > 3 or y < -3. A deletion spanning 2 consecutive probes with y < -3
can be appreciated.
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Figure 2: Heterozygous deletion example. Log R ratio plot. Scatter points represent
normalized log2 ratios (y) for probes along the chromosome. A segment was considered
to be significant if y > 1.5 or y < -1.5. A deletion spanning 2 kb y < -1.5 can be
appreciated.
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A previously described high-resolution CNV detection algorithm, the PennCNV
algorithm 87, was used to infer CNVs from the signal intensity data. This algorithm
incorporates multiple sources of information, including total signal intensity and allelic
intensity ratio at each SNP marker, the distance between neighboring SNPs, the allele
frequency of SNPs, as well as family information when available. We set a threshold at 2
SNPs for homozygous deletions and 10 SNPs for heterozygous deletions to avoid false
positive calls. This threshold was previously shown to result in a false positive rate lower
than 1% for high-quality samples 87, 88.
To define common and rare CNVs we mapped these CNVs to the UCSC genome browser
for comparison with those previously identified in other publications, or with those
included in the database of genomic variants (http://projects.tcag.ca/variation). The
common and rare CNVs were defined as those that occurred at a frequency of >1% or
<1% in general populations. The CNVs which were not detected in control subjects and
in the database of genomic variants were considered to be possibly disease causing.
Genechip analysis was performed by the author and by laboratory personnel.

Inbreeding Coefficient
Plink software, a whole genome association analysis toolset, was used to calculate the
inbreeding coefficient for each individual patient using the B allele signal data.89 The
Inbreeding coefficient is a measure of how close two people are genetically to each other.
Plink calculates the inbreeding coefficient based on the observed versus expected number
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of homozygous genotypes given a large number of SNPs in a homogeneous sample.
Inbreeding coefficient calculations were performed by the author and laboratory
personnel.

Homozygosity Mapping

Plink software was used to conduct runs of homozygosity for each individual patient
using the B allele signal data.89 In brief, the Plink algorithm performs a run of
homozygosity by taking a window of X SNPs and sliding this across the genome. At each
window position it determines whether this window looks 'homozygous' enough (yes/no)
(i.e. allowing for some number of heterozygous or missing calls). Then, for each SNP, it
calculates the proportion of 'homozygous' windows that overlap at that position. It
creates a call for segments based on this metric, e.g. based on a threshold for the average.
Homozygous runs were performed using the 100 SNP, 1000 kb windows with SNP
densities of 1 SNP per 50 kilobases. One heterozygous SNP call and 5 missing SNP calls
were allowed per homozygous window. Homozygosity runs were performed by the
author and laboratory personnel.
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Candidate Gene Mutational Analysis

Exon-intron boundaries of the candidate genes were determined based on the University
of California at Santa Cruz (UCSC) Genome Browser (NCBI Build 36.1). PCR primers
were designed using PRIMER3 (http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi). . The Basic Local Alignment Search Tool
(http://www.ncbi.nlm.nih.gov/blast/) was used for these primers. Exon amplicons were
amplified and sequenced using standard techniques. Mutational analysis was performed
by the author and by laboratory personnel.

Quantitative RT-PCR

Array CNV analysis results were confirmed with quantitative RT-PCR using the standard
curve method for absolute quantization. Primers were designed using Primer Express
Software, version 2.0 (Applied Biosystems), with the following criteria: amplicon size of
80 to 200/250 bp, GC content of 20 to 80%, no more than two guanines or cytosines in
the primer 3’ end, and melting temperature (Tm) of 59 to 60°C. Finally, the Basic Local
Alignment Search Tool (http://www.ncbi.nlm.nih.gov/blast/) was used for these primers.

The experimental design and calculations were performed as described by Applied
Biosystems (User Bulletin #2). To determine copy number changes, fourfold ranges of
five different serial dilutions from five pooled normal control DNA samples were used.
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In addition, we used 5 ng of genomic DNA from the patient’s DNA and pooled normal
control DNA. The RT-PCRs were performed in triplicate for each reaction. The 15-µl
reactions contained 1X final concentration of Power SYBR Green PCR Master Mix (part
number 4367660, Applied Biosystems) and 400 nM of each primer (Invitrogen). Each
experiment was performed using a 384-well optical PCR plate and the Applied
Biosystems machine (model 7900HT) with default cycling conditions.

A standard curve was created using the calculated threshold cycle of each dilution for
each gene. Amplifications were performed on the same diluted samples using primers for
the reference and target genes. For all experimental samples, the target quantity was
determined from the standard curve and divided by the target quantity of the normal
reference DNA. To assess reaction specificity and to verify product identity, melting
curve analysis was performed following amplification. We used the standard curves with
an efficiency between 90% and 100%, which corresponds to a slope between 23.58 and
23.20. Quantitative PCR was performed by the author and laboratory personnel.
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RESULTS

Patient Collection

To this date, 563 patients with malformations of cortical development and
syndromic neurodevelopment diseases have been collected from Yale-New Haven
Hospital as well as from collaborators in Europe. Of these 563 patients, 252 patients were
diagnosed with cortical malformations and were included in this study. Patients within
the designation of cortical malformations included patients diagnosed with
polymicrogyria (20), schizencephaly (16), developmental anomaly/ dysplasia (39), and
broadly as malformations of cortical development not specified (MCD - 95). 130 patients
were genotyped on 370k microarray Illumina Human CNV bead chips, while 119
patients were genotyped on the Illumina 610 Quad chips. Beadchip data from six (6)
chips with call rates less than 97% was considered to be of poor quality and was excluded
from this study. Genotype analysis also revealed three duplicates, which were removed as
well. Sex phenotype on the bead chip data for each patient was also cross-matched with
the reported sex to validate the integrity of the each patient sample.
A control group composed of forty (40) patients with a diagnosis of renal tubular
acidosis and of self-reported consanguinity was also genotyped on 370k Human CNV
Illumina bead chips.
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Figure 3: Demographics of Neurogenetics cohort. Total number of patients
currently in the cohort is 563 including 252 patients with the diagnosis of cortical
malformations.

32

Figure 4: Demographics of patients with cortical malformations within the
Neurogenetics Cohort. Total number of patients with cortical malformations is
252. MCD stands for malformations of cortical development not specified.
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Copy Number Variant Analysis

Analysis for copy number variants was performed using the Penn CNV algorithm in
conjunction with visual inspection of the signal intensities on the Beadstudio plataform.
Because of the difference in SNP densities between the two microarray platforms, results
are presented divided.

Copy Number Variant Analysis of patients on Illumina 370 Human CNV (N=127)

Copy number variant analysis of the 127 patients genotyped on the Illumina 370 Human
CNV bead chips revealed 20 homozygous deletions and 237 heterozygous deletions. Of
the 20 homozygous deletions, 7 contain or are within genes. Comparing these seven copy
number variants with the published reports and database of human variation eliminates
six areas where there is evidence of variability in the general population. One intergenic
deletion has not previously been reported.

Copy Number Variant Analysis of patients on Illumina 610 Quad (N=119)

Copy number variant analysis of the 119 patients genotyped on the Illumina 610 Quad
Chips revealed 593 homozygous deletions and 840 heterozygous deletions. Of the 593
homozygous deletions, 130 contain or are within genes. Comparing these 130 copy
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number variants with the published reports and database of human variation eliminates
128 areas where there is evidence of variability in the general population. Two exonic
homozygous deletions are not previously reported, and are located in the VLDLR gene
(see below).

Copy Number Variants on Illumina 370 Human CNV

GROUP

# PATIENTS

HZ

HET

NON-

DELETIONS

DELETIONS

REPORTED

CORTICAL DYSPLASIA

5

1

4

0

DEVELOPMENTAL ANOMALY

37

6

35

0

DNET

9

2

6

0

HETEROTOPIA

6

0

5

0

LISSENCEPHALY

22

2

37

0

MCD

20

5

29

1

MULTIPLE

3

2

58

0

POLYMICROGYRIA

17

1

35

0

SCHIZENCEPHALY

8

1

28

0

127

20

237

0

Total

Table 5: Genomic Deletions per Malformations of Cortical Development Sub-group in patients
genotyped on Illumina 370 Human CNV Bead Chip. Hz, Homozygous; Het, Heterozygous.

35
Copy Number Variants on Illumina 610 Quad

GROUP

# PATIENTS

HZ

HET

NON-

DELETIONS

DELETIONS

REPORTED

CORTICAL DYSPLASIA

7

25

35

0

PACHYGYRIA

8

35

58

2

DNET

1

6

4

0

HETEROTOPIA

4

23

25

0

LISSENCEPHALY

8

33

94

0

MCD

74

395

500

1

MULTIPLE

6

24

47

0

POLYMICROGYRIA

2

13

15

0

SCHIZENCEPHALY

8

39

62

0

119

593

840

0

Total

Table 6: Genomic Deletions per Malformations of Cortical Development Sub-group in patients
genotyped on Illumina 610 Quad Bead Chips. Hz, Homozygous; Het, Heterozygous.

Copy Number Variant Analysis of Controls

Copy number variant analysis of the 40 controls on the Illumina 370 Bead chips revealed
fifteen homozygous deletions and 139 heterozygous deletions. Of the fifteen homozygous
deletions, seven are within genes. Comparing these 7 copy number variants with the
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published reports and database of human variation eliminates one area of common
variability. Five homozygous mutations are known to cause autosomal recessive cases of
renal acidosis.

Figure 5: Homozygous deletions within genes in the control population (N = 40).
Mutations in CLCNKA and CLCNKB, part of the family of voltage-gated chloride
channels, have been associated with Barter’s syndrome Type 4, an autosomal recessive
disorder defined by hypokalemic metabolic acidosis (OMIM # 602522). Mutations in
FRAS1, which encodes a putative extracellular matrix (ECM) protein, is mutated in
Fraser syndrome (OMIM #219000).
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Copy Number Variant Analysis of Heterozygous Deletions and Amplifications

We are currently in the process of further investigating identified heterozygous deletions
as well as amplifications on our samples (results not shown) in order to identify
mutations that might be disease causing in our cohort.

Diffuse Villous Hyperplasia of the Choroid Plexus

Background

Diffuse villous hyperplasia of the choroid plexus (DVHCP) is defined as diffuse
enlargement of the entire choroid plexus occurring throughout the length of the choroid
fissure. DVHCP is a rare cause of hydrocephalus which according to contemporary case
reports, is not adequately treated by shunting; It is a rare disorder, having been reported
in only a handful of cases90-94. Hydrocephalus and congenital malformations of the
Dandy-Walker Complex are not often associated with chromosomal abnormalities.
Herein we describe a case of a female child born with hydrocephalus, and multiple
craniofacial anomalies including cleft palate and lip. CT scan demonstrated DVHCP and
hypoplasia of the cerebellar vermis.
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Figure 6: Axial non-contrast head CT. Representative images through the lateral
ventricles (A) and third ventricle (B) demonstrate hydrocephalus, diffuse enlargement of
the arachnoid spaces, diffuse villous hyperplasia of the choroid plexus and hypoplasia of
the cerebellar vermis. (C) Axial T1-weighted MRI with contrast further highlights the
diffusely enlarged choroid plexus within the lateral ventricles. (D) Sagital T1-weighted
MRI without contrast demonstrates the hypoplastic cerebellar vermis consistent with
Dandy-Walker malformation. (E) Intra-op composite endoscopic view of the right
foramen of Monroe revealing the dense choroid plexus.
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High-resolution array mapping of the child’s genomic DNA demonstrated
complete tetrasomy of the short arm of chromosome 9, establishing the karyotype of the
child as 46XX+9p. Complete, non-mosaic tetrasomy 9p is an extremely rare, typically
fatal syndrome with a broad range of clinical features ranging from normal phenotype to
Dandy-Walker Malformation and perinatal demise. This is the first description of this
genetic anomaly using high-resolution arrays, in a viable child broadening the clinical
spectrum to include diffuse villous hyperplasia of the choroid plexus leading to
hydrocephalus.

Clinical Presentation

The child presented to neurosurgical attention at the age of three months with an
increasing head circumference, which crossed percentiles and failure to thrive. She was
the product of a term pregnancy, born to healthy parents with no prior history of genetic
disease. On examination, the head circumference was 42.5 cm. Sutures were splayed
open and the anterior fontanelle was widened and tense. The child had a unilateral (left)
cleft lip and palate, low-set ears, micrognathia, and beaking of the nose. Otherwise, there
were no other noted systemic signs or symptoms. CT/MRI demonstrated
ventriculomegaly, hyperplasia of the choroids plexus in the lateral ventricles, and a
Dandy-Walker malformation variant.
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Intervention/Technique
The patient was taken to the operating room and a ventriculoperitoneal shunt was
placed under endoscopic guidance. Intra-op, marked hyperplasia of the choroid plexus
was noted (Figure 1E). The CSF overproduction overwhelmed her abdominal absorptive
capacity leading to CSF ascites and wound dehiscence. After an antibiotic course and
shunt externalization (her CSF drainage was in excess of 1L/day), endoscopic-assisted
surgical debulking of her bilateral choroid plexus hyperplasia was performed. The shunt
was then successfully internalized. After two years of follow-up, her ventriculomegaly is
gradually resolving as her shunt continues to function.

Copy Number Variant Analysis

Using the Beadstudio v3.3 genotyping software (Illumina, San Diego, CA, USA),
analysis of the data revealed tetrasomy of the entire short arm of chromosome 9 (Figure
2). No other chromosomal anomalies were seen, indicating a karyotype/genotype of
46XX+
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Figure 7: High-resolution SNP/CNV array analysis of the patient’s genomic DNA.
Tetrasomy of the short arm of chromosome 9: 46XX+9p (Illumina BeadStudio
Chromosome 9 window, b-allele frequencies).

Cerebellar Atrophy and Pachygyria

Background

Non progressive human congenital ataxias are a rare, heterogeneous group of disorders
that are characterized by motor disability, muscular hypotonia, incoordination, and
impaired motor development.95-97 They present initially with general symptoms such as
delayed motor milestones and hypotonia during the post natal period and early childhood,
followed by the gradual onset of ataxic gait during the first few years of life. Some cases
improve as motor functions develop, while others worsen early during infancy as motor
demands increase on coordination. 97
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This heterogeneous group of disorders has been associated with multiple other diseases
including brain malformations, genetic syndromes, and congenital infections. It is
thought that 4% of cases are due to a perinatal cause, while 45% of the cases are due to
prenatal causes. The remaining half are speculated to be of unknown etiology.96 Of the
associated brain malformations, cerebellar hyoplasia seems to be the most common,
occurring in slightly less than 50% of cases. 98 The most severe cases have been noted to
have marked hyoplasia of the vermis ,and mild to moderate involvement of the
neocerebellum, but in other cases the neuroimaging findings have not correlated with the
severity of the disease.98

Evaluation of the distinguishable, inherited congenital ataxia syndromes with cerebellar
hypoplasia has led to the identification of novel genes involved in the embryonic
development of the cerebellum. Mutations in the Reelin gene have been identified to
cause autosomal recessive lissencephaly with cerebellar hypoplasia 99, and PTF1a
mutations have been linked to cerebellar agenesis and neonatal diabetes.100 Studies on
Joubert syndrome, a group of recessively inherited conditions characterized by congenital
ataxia, hypotonia, episodic breathing, mental retardation, and a specific malformation of
the brainstem, cerebellum, and peduncles, have led to the identification of several genes
including AHI1, NPHP1, CEP290, MKS3, and RPGR1L; encoding cilia-like functioning
and modular scaffolding proteins.101-112

Recently, mutations in the Very Low Density Lipoprotein Receptor (VLDLR) have been
identified in patients in the Turkish 113 114, Iranian 115 and Hutterite 116 populations with
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cerebellar atrophy and congenital ataxia following an autosomal recessive type of
inheritance. These findings in conjunction with advances in the roles of these genes in
mouse models have led to further understanding of the Relin-Vldlr pathway and its role
in the developing cerebellum.

Clinical Presentation

The family originates from southeast Turkey. The two affected siblings are a product of a
self-reported consanguineous first cousin marriage, ages 11 (NG 374-1) and 8 (NG 3742) at the time of presentation (Figure 8). Both patients were delivered by uneventful csections with normal weights and heights at birth. They started holding their heads
around 40 days, began to sit unsupported at age 1, and started walking at age 18 months
with support from their hands. This is in contrast to unaffected children, which are able to
walk unassisted on average by 15 months of age. The patients’ gait is severely ataxic, and
they demonstrate hyperactive deep tendon reflexes. They do not exhibit any tremor.
Examination also reveals dysarthria, dysmetria, and dysdiadokinesis, and they cannot
construct full sentences. The older patient exhibits selective mutism, constructing full
sentences only when speaking to himself. MRI scans from both affected siblings show
pachygyria and cerebellar atrophy (Figure 8).
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Figure 8
A. Representative pedigree of family NG-374. Affected members are identified
by filled symbols. Diagonal lines indicate deceased family members. Circles represent
female and squares represent male family members.
B. Magnetic Resonance Imaging (MRI) of the brain of affected siblings. Sagittal
T1 (1,2) and Coronal T2 (3,4) weighted images demonstrate prominent pachygyria and
hypoplasia of the cerebellar vermis and hemispheres in both patients NG 374-1 (1,3) and
NG 374-2 (2,4).
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Copy Number Variant Analysis

Homozygosity mapping of the affected siblings on Beadstudio v3.3 identified a 10 kb
homozygous block shared by both patients in chromosome 9 starting at 102,542 bps and
ending at 10,533,899 bps. Affected-only copy number variation analysis of both siblings
on Human610-Quad beadchips using the PennCNV algorithm and visual inspection of
the plotted intensities on Beadstudio v3.3 showed a shared homozygous deletion (Figure
9) on chromosome 9 spanning approximately 9.7 kb with the first and last deleted SNP
markers being rs2375994 and rs10967306. The deletion was noted to be within the
previously identified homozygous block on both patients. Compared to published reports
of genomic variation in the Database of Human Variation
(http://projects.tcag.ca/variation/), this area does not appear to be an area of common
variability. Homozygous deletions in the VLDLR gene were absent in 300 other Turkish
patients with malformations of cortical development that were genotyped.

PCR / QPCR Results

PCR analysis of the patients and parents revealed a homozygous deletion in the VLDRL
gene encompassing exon 2, exon3, and exon 4 and no comparable homozygous deletion
in the parents (Figure 9). Real time PCR analysis of the region confirmed the
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homozygous deletion in both siblings, and also found a heterozygous deletion in both
parents when compared to controls. (Figure 5) Sequence analysis revealed a 21,218 bp
deletion including exons 2 ,3, and 4 and part of exons 1 and 5 that began on 2612144 bps
and ends on 2633338 bps.
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Figure 9:
A. Log R ratio plot of the genome-wide SNP based genotyping demonstrates a region on
Chromosome 9 with a microdeletion in the VLDLR gene shared by both patients. Scatter
points represent normalized log R ratios (y) for probe intensities along the chromosome.
Negative values below y = -1 represent a homozygous deletion spanning 9 consecutive
probes shared by both patients. Shaded areas represent areas of autozygosity.
B. Closer view of the deleted region on Chromosome 9 spanning 21,218 bps
including the 9 consecutive SNPs. Deleted segment is represented by a black bar.
C. Quantitative PCR results of exon 3 of the VLDLR gene within the deleted
segment showing homozygous deletions in both patients and heterozygous deletions in
both parents.
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Inbreeding Coefficient Estimates

Inbreeding coefficient estimates were obtained for each patient using the Inbreeding
coefficient function of the Plink software. Because of the differences in the SNP marker
densities, results were divided by beadchip type. The mean for the 127 patients
genotyped on the Illumina Human CNV 370k was 0.034 with a range of -0.01 to 0.203.
The mean for the 119 patients genotyped on the Illumina 610 Quad beadchip was 0.022
with a range of -0.014 to 0.175. The mean for the 40 controls genotyped on the Illumina
370k was 0.087 with a range of 0.015 to 0.22. The overall mean for all the 245
genotyped patients was 0.028 with a range of -0.012 to 0.203.
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Table 7: Inbreeding coefficients for each subgroup. Inbreeding coefficients were
compared between patients that had self reported consanguinity versus patients with
unknown or reported no consanguinity. The mean of the inbreeding coefficients for
patients that were reported as consanguineous was 0.075 while the mean of the patients
reported as non consanguineous or unknown was 0.005

Table 8: Inbreeding coefficients for patients reported as consanguineous and
patients reported as non-consanguineous. Inbreeding coefficient mean for patients
reported as consanguineous was significantly higher than the inbreeding coefficient for
patients reported as non-consanguineous.
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Homozygosity Mapping

We are currently in the process of performing homozygosity mapping on our samples
(results not shown) in order to find common homozygous areas that may harbor
homozygous mutations responsible for autosomal recessive diseases in the
consanguineous cohort. Inbreeding coefficients will be used to select a consanguineous
group of patients.
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DISCUSSION

The results of the two studies presented above demonstrate the utility of SNP genotyping
and CNV analysis in uncovering the genetic basis of malformations of cortical
development. Specifically, two diseases are presented in this manuscript: choroid
hyperplasia, and cerebellar atrophy as part of the ongoing effort to identify diseasecausing mutations in our cohort of patients with cortical malformations.

Choroid Hyperplasia

First described in 1973117, tetrasomy 9p as a rare congenital chromosomal anomaly. Since
that time, approximately 50 cases have been reported with a wide variety of phenotypic
variants. The severity of phenotype appears to correlate with the degree of mosaicism
with non-mosaic cases resulting in perinatal demise in the first few weeks of life118-123.
The majority of cases of 9p tetrasomy are mosaic and thus accounting for the diverse
range of mild to severe phenotypes. Commonality among the phenotypes has allowed for
a syndrome to emerge consisting of hypertelorism, beaked nose, cleft palate and midface
abnormalities, ear malformations, skeletal and joint abnormalities, hypoplasia of the nails
and digits, hypertelorism, urogenital anomalies, developmental retardation, hypotonia,
open sutures/wide fontanelles, clinodactyly, growth retardation, and
ventriculomegaly/macrocephaly or microcephaly119, 120, 124, 125.
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Three prior infants have been described with choroid plexus pathology in
association with 9p duplications. Norman et al reported two patients, one with
hemorrhagic choroid plexus hyperplasia, early perinatal demise, and mosaic tetrasomy of
9p karyotype of 47,XY,+idic(9)(q11) and a second child developed hydrocephalus at 11
months with choroid plexus hyperplasia on ultrasound and a trisomy 9p karyotype of 47,
XX, +der(9)t(9;?)(q13;?)126. The unknown, precise definition of the duplication
demonstrates the low-resolution of Giemsa banding and traditional FISH analysis.
Shapiro et al described a patient with bilateral choroid plexus “papillomata” and partial
9p tetrasomy, partial 9p trisomy and a karyotype of 47,
XX,+psudic(9)t(9;9)(9pter→9q22.1::9q12 or 13→9pter)123. Hydrocephalus was initially
thought to be a feature not seen in non-mosaic 9p duplications125, however, numerous
children are reported with mosaic and non-mosaic 9p duplications (trisomy or tetrasomy,
complete or partial) associated with hydrocephalus119, 120, 122, 125, 127-130 or hydrocephalus
specifically from Dandy-Walker malformations118, 131-139. Only previously mentioned
two papers specifically discuss the presence of choroid plexus abnormalities123, 126.
DVHCP is a rare disorder and results from treatment are limited to those reported
in fewer than 10 reported cases. Two reports have demonstrated complete resolution of
hydrocephalus after choroid plexus resection, however there was associated morbidity
with the approach140, 141. The majority of cases argue for debulking of the choroid plexus
and subsequent shunting as externalized ventricular drainage failed to demonstrate
complete cessation of CSF overproduction90-94, 142. This was the approach employed by
our group.
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The presence of 9p duplications has been examined in choroid plexus tumor
specimens: cytogenic studies on 49 choroid plexus tumors found 9p duplication in 50%
of choroid plexus papillomas and 33% of choroid plexus carcinomas143, while others
have not been able to demonstrate consistent 9p duplications in choroid plexus tumors126,
144

. The gain of 9p was associated with a significantly longer survival, and better

prognosis for patients with choroid carcinomas143. There likely exist genes on 9p, which
play a role in choroid plexus growth and development. This report expands the spectrum
of phenotypic anomalies associated with non-mosaic tetrasomy 9p syndrome to include
DVHCP. As we refine the intervals on chromosome 9p involved, we will understand the
relation of genes on 9p to midline anomalies and the growth and tumorigenesis of the
choroid plexus.

Cerebellar Atrophy

The VLDLR gene is composed of 19 exons, spans 32 kb, and encodes a protein that is
part of the Low Density Lipoprotein (LDL) gene family. It encodes a five domain, ligand
binding receptor that is characterized by an N terminal 328-amino acid cysteine-rich
ligand-binding domain, a 396-amino acid EGF precursor homology domain, a 46-amino
acid O-linked sugar domain, a 22-amino acid single transmembrane domain, and a 54amino acid cytoplasmic COOH terminal domain. In humans two forms of the receptor
have been identified, one that resembles the LDL receptor, and an alternative form with
four domains that lacks the O-linked sugar domain. 145.The VLDLR has been suggested
to be important in the metabolism of apoprotein-E containing triacylglycerol-rich
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lipoproteins, beta-migrating VLDL and intermediate-density lipoproteins.146 It is also part
of the Reelin signaling pathway 147.

Reelin is an extracellular glycoprotein that is secreted by several types of neurons,
including the Cajal-Retzius cells in the marginal zones of the cortex during embryonic
development.148 It is important in the regulation of neuronal migration and positioning in
the developing brain, as well as modulating synaptic plasticity and long term potentiation
in the hippocampus during adulthood149. It has also been shown to stimulate dendrite and
dentritic spine development 150, and the continual migration of neuroblasts generated in
adult neurogenesis sites such as the subventricular zone and dentate nucleus.151 It is
thought to interact through one of two receptors, the VLDLR and the Apolipoprotein-E
Receptor Type 2 (ApoER2)152, on several intracellular proteins including Dab-1, an
adapter protein. 147 According to a recent study, these two receptors might have divergent
roles with VLDLR conducting the stop signal for migrating neurons while ApoER2 is
essential for the migration of late-born neocortical neurons.153

Reelin -/- mice were originally described by Falconer et. al in 1951 and were named for
their distinct ataxic and “reeling” gait.154 Affected mice exhibit failed migration of the
Purkinje cells, inverted cortical lamination, cerebellar hypoplasia, and ataxia.155-158. In
humans, homozygous mutations of the Reelin gene are responsible for a type of
autosomal recessive lissencephally, Norman-Roberts syndrome99. Another protein found
to have a role in lissencephally, Pafahb1 (LIS1), was also shown to be part of the reelin
pathway, interacting with the intracellular segment of VLDLR.159
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Mutations in the VLDRL gene have been previously described both in humans and in
animal models. Vldlr -/- mice appear to be grossly and neurologically normal, but contain
ectopically located Purkinje cells in the cerebellum and radially aligned neurons in the
cortex that appear to have failed to distribute152, 160. The first mutation observed in a
human case in the gene was in the Hutterite population116 where a 199-kb homozygous
deletion encompassing the complete VLDLR gene and possibly adjacent regulatory
regions was noted to be responsible for the “Dysequillibrium Syndrome”. Originally
described in the 1980s, the “Dysequillibrium Syndrome” in the Hutterite population
consisted of an autosomal recessive constellation of non-progressive cerebellar ataxia,
mental retardation, and cerebellar hypoplasia161, 162. Patients were also noted to have
delayed ambulation, strabismus, mild cortical simplification on MRI, and short stature
(15%). However, this deletion also encompassed adjacent regulatory regions, and
possibly a second gene. It was therefore unclear whether a mutation in VLDRL could
solely explain the syndrome in its entirety. Subsequently, a homozygous nucleotide
substitution in exon 10 resulting in a premature stop codon in the VLDLR gene identified
in an Iranian family with Disequilibrium Syndrome gave rest to this argument, and
indeed showed that a truncated VLDRL protein in isolation was a satisfactory cause of
DES.

Since then, three Turkish families have been reported with Unertan Syndrome, which is a
rare autosomal recessive neurodevelopmental condition with cerebellar and cortical
hypoplasia accompanied by mental retardation, primitive and dysarthric speech, and most
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notably, quadrupedal locomotion163. One non-sense and one frameshift mutation (in two
separate families) resulting in premature stop codons in exons 5 and 17 were identified in
the Turkish families with Unertan syndrome, presumably causing the VLDLR to lack
transmembrane and signaling domains.

The cause of differences in locomotion phenotype are unclear, but Ozcelik et al. argue
that it might be a result of different mutations in the same gene leading to different
phenotypes, and variable expressions of the disease phenotype.114, 164 Ozcelik et al
explain that they believe quadrupedal gait to be the result of their reported homozygous
deletions resulting in this specific gait compared to the mutations resulting in the
Dysequillibrium syndrome. In contrast, Herz and Humphrey argue that quadrupedal
locomotion has developed in a subset of reported patients with VLDLR deletions as an
adaptive process to the severe truncal ataxia, and the Unertan syndrome does not
represent a separate genetic entity165, 166. They believe that rural surfaces, imitation of the
behavior of other affected siblings, lack of medical attention, and social acceptance of
quadrupedal gait without correction are believed to have contributed to the development
of quadrupedal gait in these patients. Even though it is true that some families were
isolated from medical attention, this claim has also been debated by the presence of
families where extensive medical care was sought, and quadrupedal gait was strongly
discouraged yet still developed.

Including our recent report, to date five different mutations in nine families have been
described in the VLDLR gene including the original description in the Hutterites.
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Structural examination of the gene and the defective protein does not reveal any
identifiable portion that seems to be responsible for quadrupedal gait. A stop codon in
exon 5 and a frameshift mutation in exon 17 both lead to quadrupedal gait in Turkish
families, whereas a stop codon in exon 10, and our recent report of a deletion affecting
exons 1-5 resulted in bipedal, ataxic gait. Thus, it is likely that DES and Unertan
syndrome are clinically, but not genetically distinct syndromes, and represent a spectrum
of disease resulting from dysfunctional VLDLR protein. Where along the spectrum an
affected patient will lay is likely the product of a complex interaction between genetic
makeup and the environment, and cannot be predicted based on the mutation alone. It is
unlikely that VLDRL represents an indispensable gene in human bipedalism and
evolution, but rather an integral part of cerebellogenesis.
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